Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indofarma Tbk. (INAF) vs Lippo Karawaci Tbk. (LPKR) Price & Performance

Indofarma Tbk.Trade
Lippo Karawaci Tbk.Trade

Price performance (Past 24H)

Key statistics

Indofarma Tbk. vs Lippo Karawaci Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Lippo Karawaci Tbk. trades at Rp61 (market cap 4.32T, 78.75M 24h volume). The key difference: Lippo Karawaci Tbk. is far larger — about 11.1× Indofarma Tbk.'s market cap. Which is the better fit depends on your goals.

INAFLPKR
Market Cap
390.51B4.32T
Volume
78.75M
Lot
787.51K
Turnover
4.81B
Average Price
61.05
Value
4.81B
Indicative Equilibrium Price
61
Indicative Equilibrium Volume
28.62K

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INAF
View details
LPKR
View details

About Indofarma Tbk.

PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.

Read more on INAF

About Lippo Karawaci Tbk.

PT Lippo Karawaci Tbk was established under the name of PT Tunggal Reksakencana on October, 1990. The Company's scope of activities includes real estate, urban development and infrastructure, industrial estate development, general facilities and infrastructure development, services and investments, both direct and indirect, either through its subsidiaries or in joint venture with other parties.

Read more on LPKR